PRELUDE THERAPEUTICS INC
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-34.7M | $-31.4M | $-33.1M | $-30.6M | $-30.4M | $-27.7M | $-28.6M | $-30.0M |
| Depreciation & Amortization | $452.0K | $426.0K | $331.0K | $279.0K | $281.0K | $278.0K | $362.0K | $337.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $6.1M | $5.5M | $5.9M | $6.7M | $6.7M | $6.3M | $5.8M | $6.4M |
| Net Cash from Operating Activities | $-23.1M | $-31.8M | $-23.6M | $-25.7M | $-27.7M | $-30.1M | $-22.9M | $-20.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $359.0K | $289.0K | $1.1M | $591.0K | $983.0K | $810.0K | $393.0K | $916.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $26.1M | $31.2M | $7.7M | $15.0M | $-75.4M | $18.0M | $1.4M | $21.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $59.0K | $-14.0K | $25.2M | $88.0K | $111.3M | $-269.0K | $155.0K | $148.0K |
| Net Change in Cash | $3.1M | $-584.0K | $9.4M | $-10.6M | $8.2M | $-12.4M | $-21.4M | $1.3M |
| Free Cash Flow | $-23.4M | $-32.1M | $-24.7M | $-26.3M | $-28.7M | $-30.9M | $-23.3M | $-21.4M |